The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis

Critical Care Medicine

Volumn 32, Issue 11, 2004, Pages 2199-2206

  Angus, Derek C ^a,e   Laterre, Pierre Francois ^b,e   Helterbrand, Jeff ^c,e   Ely, E Wesley ^d   Ball, Daniel E ^e   Garg, Rekha ^e   Weissfeld, Lisa A ^f   Bernard, Gordon R ^g  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c GENENTECH INC   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drotrecogin; Follow up studies; Mortality; Protein C; Recombinant human activated protein C; Severe sepsis; Survival analysis; Xigris

Indexed keywords

DROTRECOGIN; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SURVIVAL TIME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTI-INFECTIVE AGENTS; APACHE; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROPORTIONAL HAZARDS MODELS; PROTEIN C; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SAMPLE SIZE; SEPSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 8544268686     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000145228.62451.F6     Document Type: Article

References (44)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Crit Care Med 1992; 20:864-874
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
3. Padkin A, Goldfrad C, Brady AR, et al: Epidemiology of severe sepsis occurring in the first 24 hours in the ICU in England, Wales, and Northern Ireland. Crit Care Med 2003; 9:2332-2338
4. Brun-Buisson C, Doyon F, Carlet J, et al: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274:968-974
5. Davies A, Green C, Hutton J, et al: Severe sepsis: A European estimate of the burden of disease in ICU. Abstr. Intensive Care Med 2001; 27(Suppl 2):S284
6. Vincent JL, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274:639-644
7. Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12:135-145
8. Dhainaut JF, Yan SB, Margolis BD, et al: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90:642-653
9. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
10. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
11. Padkin A, Rowan K, Black N: Using high quality clinical databases to complement the results of randomised controlled trials: The case of recombinant human activated protein C. BMJ 2001; 323:923-926
12. Siegel JP: Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002; 347:1030-1034
13. Warren HS, Suffredini AF, Eichacker PQ, et al: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030
14. Hinds CJ: Treatment of sepsis with activated protein C. BMJ 2001; 323:881-882
15. Linde-Zwirble WT, Clermont G, Van Hout B, et al: Increased survivorship with drotrecogin alfa (activated) in the treatment of severe sepsis: The effect on hospital costs. Abstr. Crit Care Med 2001; 29:A1
16. Manns BJ, Lee H, Doig CJ, et al: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 993-1000
17. Somogyi-Zalud E, Zhong Z, Lynn J, et al: Dying with acute respiratory failure or multiple organ system failure with sepsis. J Am Geriatr Soc 2000; 48(Suppl-5):S140-S145
18. Quartin AA, Schein RM, Kett DH, et al: Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997; 277:1058-1063
19. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123
20. Brun-Buisson C, Meshaka P, Pinton P, et al: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588
21. Perl TM, Dvorak L, Hwang T, et al: Long-term survival and function after suspected gram-negative sepsis. JAMA 1995; 274:338-345
22. Cohen J, Guyatt G, Bernard GR, et al: New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001; 29:880-886
23. Harrington D, Fleming T: A class of rank test procedures for censored survival data. Biometrika 1982; 69:553-566
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
25. Pocock SJ, Clayton TC, Altman DG: Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet 2002; 359:1686-1689
26. Klein JP: Small sample moments of the estimators of the variance of the Kaplan-Meier and Nelson-Aalen estimators. Scand J Stat 1991; 18:333-340
27. Moine P, Timsit JF, De Lassence A, et al: Mortality associated with late-onset pneumonia in the intensive care unit: Results of a multi-center cohort study. Intensive Care Med 2002; 28:154-163
28. Quality of Life After Mechanized Ventilation in the Elderly Study Investigators. Two-month mortality and functional status of critically ill adult patients receiving prolonged mechanical ventilation. Chest 2002; 121:549-558
29. Jaagosild P, Dawson NV, Thomas C, et al: Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Arch Intern Med 1998; 158:1081-1089
30. Clermont G, Angus DC, Linde-Zwirble WT, et al: Does acute organ dysfunction predict patient-centered outcomes? Chest 2002; 121: 1963-1971
31. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
32. Katz S, Akpom CA: A measure of primary sociobiological functions. Int J Health Serv 1976; 6:493-508
33. ICH E6: Good clinical practice: Consolidated guideline. Federal Register 2 A.D.;62: 25691-25709
34. Sands KE, Bates DW, Lanken PN, et al: Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997; 278:234-240
35. Hartman ME, Angus DC: Variation in sepsis care: A wake-up call. Crit Care 2003; 7:211-213
36. Yu DT, Black E, Sands KE, et al: Severe sepsis: Variation in resource and therapeutic modality use among academic centers. Crit Care 2003; 7:R24-R34
37. Hill AB. Principles of medical statistics. Ninth Edition. London, Lancet, 1971
38. Wedel H, Demets D, Deedwania P, et al: Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. Am Heart J 2001; 142:502-511
39. Ely EW, Laterre PF, Angus DC, et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
40. Vincent JL, Angus DC, Artigas A, et al: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31:834-840
41. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
42. Angus DC, Linde-Zwirble WT, Clermont G, et al: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11
43. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
44. Dhainaut JF, Laterre PF, LaRosa SP, et al: The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results. Crit Care Med 2003; 31:2291-2301